News Search Results
Mar 25, 2025, 08:00 ET Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI
More news about: Anixa Biosciences, Inc.
Mar 25, 2025, 08:00 ET AngeoPro Yeast Protein Wins 2025 World Best Ingredient Innovation Award, Pioneering a New Era of Sustainable Protein
ever-growing demand for plant-based alternatives that deliver exceptional nutrition without compromising on taste or texture. Through advanced biotechnology, AngeoPro offers a complete amino acid profile, superior digestibility, and exceptional functional properties, making it ideal for applications
More news about: Angel Yeast
Mar 25, 2025, 07:30 ET Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Mar 25, 2025, 07:30 ET Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 25, 2025, 07:09 ET Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides
natural product research, NAICONS collaborates with public and private institutions worldwide to drive innovation in drug discovery, agriculture and biotechnology, unlocking the potential of microbial diversity to develop next-generation solutions. Photo -
More news about: MOA Technology
Mar 25, 2025, 06:30 ET Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
BOSTON, March 25, 2025 /PRNewswire/ -- Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful closing of
More news about: Hillstar Bio
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
Mar 24, 2025, 18:04 ET Investor Alert: Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit
persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering
More news about: Robbins LLP
Mar 24, 2025, 17:31 ET CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight
including Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon
More news about: DelveInsight Business Research, LLP
Mar 24, 2025, 17:06 ET Natural Cosmetics Market Projected to Reach $35.96 Billion by 2032, Growing at 7.5% CAGR from 2025 --Exclusive Report by Meticulous Research®
adoption of biodegradable packaging solutions to minimize environmental impact. Innovation is accelerating in the sector, with companies leveraging biotechnology to develop sustainable lab-grown natural ingredients that maintain product efficacy while reducing environmental footprint. Growth Opportunities
More news about: Meticulous Market Research Pvt. Ltd.
Mar 24, 2025, 16:47 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 24, 2025, 16:30 ET Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal
More news about: Nanoscope Therapeutics
Mar 24, 2025, 15:55 ET Algal Pigments Market Projected to Reach $718 Million by 2032, Growing at 7.2% CAGR from 2025 | Meticulous Research®
Co., Ltd. (Japan)Algatechologies Ltd. (Israel)Zhejiang Binmei Biotechnology Co., Ltd (China)Algae Health Sciences (U.S.)Sochim International S.p.A. (Italy)Merck
More news about: Meticulous Market Research Private Limited
Mar 24, 2025, 14:23 ET NASA Invites Media to SpaceX's 32nd Resupply Launch to Space Station
[email protected]. Each resupply mission to the station delivers scientific investigations in the areas of biology and biotechnology, Earth and space science, physical sciences, and technology development and demonstrations. Cargo resupply from U.S. companies ensures a national
More news about: NASA
Mar 24, 2025, 11:00 ET ICLR INVESTOR ALERT: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Mar 24, 2025, 10:45 ET Digestive Health Products Market Surges to USD 102.5 Billion by 2033, Propelled by 4.5% CAGR - Verified Market Reports®
gastrointestinal disorders, coupled with a shift toward preventive healthcare, is accelerating market expansion. Companies are leveraging cutting-edge biotechnology and microbiome research to develop innovative solutions, enhancing product efficacy and consumer appeal. Key challenges encompass stringent
More news about: Verified Market Reports
Mar 24, 2025, 10:30 ET Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
[email protected] (973) 723-7832 About Regor Therapeutics GroupRegor Therapeutics Group is a clinical-stage biotechnology company, headquartered in Cambridge, MA and with operations in Houston, TX,
More news about: Sermonix Pharmaceuticals; Regor Therapeutics Group
Mar 24, 2025, 08:12 ET Abu Dhabi Gears Up to Host 25,000 Global Participants at AIM Congress in April
diverse sectors, including intelligent agriculture, energy, infrastructure, finance & stock exchange, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics & transportation, water technology, tourism, and education. The
More news about: AIM Congress
Mar 24, 2025, 08:00 ET Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued
More news about: Anixa Biosciences, Inc.
Mar 24, 2025, 08:00 ET SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
populations. About SineuGene SineuGene Therapeutics Co., Ltd., often referred to as "SineuGene," is a biotechnology company focused on developing innovative therapies for neurological diseases. Established in late 2021, the company builds on over a decade of scientific
More news about: SineuGene Therapeutics
Mar 24, 2025, 07:59 ET Abu Dhabi Gears Up to Host 25,000 Global Participants at AIM Congress in April
diverse sectors, including intelligent agriculture, energy, infrastructure, finance & stock exchange, ICT, manufacturing, medical tourism, biotechnology, medical technology, pharmaceuticals, international trade, logistics & transportation, water technology, tourism, and education. The
More news about: AIM Congress
Mar 24, 2025, 05:45 ET ICLR LAWSUIT ALERT: The Gross Law Firm Notifies ICON Public Limited Company Investors of a Class Action Lawsuit and Upcoming Deadline
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Gross Law Firm
Mar 23, 2025, 19:56 ET Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced IND clearance
More news about: Clover Biopharma
Mar 21, 2025, 13:50 ET Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031--Exclusive Report by Meticulous Research®
North America held the largest share of the market, primarily driven by significant R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cardiovascular diseases, a well-established healthcare infrastructure, government support for biomarker research
More news about: Meticulous Market Research Pvt. Ltd.